Redox control of cardiovascular homeostasis by angiotensin II

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3022-3032

  Sunggip, Caroline ^a   Kitajima, Naoyuki ^a   Nishida, Motohiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cysteine modification; Nitric oxide; Reactive oxygen species; Receptor; Senescence

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; ENZYME ACTIVATION; ENZYME MECHANISM; HOMEOSTASIS; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; CARDIOVASCULAR SYSTEM; CELL AGING; GENES, RAS; HOMEOSTASIS; HUMANS; MITOCHONDRIA; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84878624648     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170008     Document Type: Review

References (154)

1. Skeggs LT, Dorer FE, Levine M, Lentz KE, Kahn JR. The biochemistry of the renin-angiotensin system. Adv Exp Med Biol 1980; 130: 1-27.
2. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Tends Pharmacol Science 2002; 23: 177-83.
3. Saito Y, Berk BC. Angiotensin II-mediated signal transduction pathways. Curr Hypertens Rep 2002; 4: L167-71.
4. Touyz RM. Reactive oxygen species as mediators of calcium signaling by Angiotensin II: implications in vascular physiology and pathophysiology, Antioxid Redox Signal 2005; 7: 1302-14.
5. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger Th. The angiotensin II receptors. International union of pharmacology XXIII. Pharmacol Rev 2000; 52: 415-72.
6. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007; 113: 210-26.
7. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Eng J Med 1994; 330: 1431-38.
8. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7-15.
9. Rajasekaran NS, Connell P, Christians ES, et al. Human. Bcrystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell 2007; 130: 427-39.
10. Dimmeler S, Zeiher AM. A "reductionist" view of cardiomyopathy. Cell 2007; 130: 401-2.
11. Tanimoto K, Sugiyama F, Goto Y, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994: 269: 31334-7.
12. Kim H, Krege J, Kluckman K, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2735-9.
13. Krege J, John S, Langenbach L, et al. Male-female differencies in fertility and blood pressure in ACE-deficient mice. Nature 1995: 375: 146-9.
14. Escher CR, Marino EM, Howard TE, et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997; 15: 2375-85.
15. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensinconverting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168: 1808-20.
16. Gurley SB, Allred A, Le TH, et al. Altered blood pressure response and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116(8): 2218-25
17. Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006; 47: 718-26.
18. Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92: 3521-5.
19. Sugaya T, Nishimatsu S, Tanimoto K, et al. Angiotensin type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995; 270: 18719-22.
20. Oliverio MI, Best CF, Kim HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II responses in AT1A receptor-deficient mice: A role for AT1B receptors in blood pressure regulation. Am J Physiol 1997; 272: F515-20.
21. 1Areceptor-deficient mice. Am J Physiol 1997; 273: F315-20.
22. Chen X, Li W, Yoshida H, et al. Targeting deletion of angiotensin type 1B receptor gene in themouse. Am J Physiol 1997; 272: F299-304.
23. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995; 377: 744-7.
24. Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011; 332: 361-4.
25. Oishi Y, Ozono R, Yano Y, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 2003; 41(3): 814-8.
26. Adachi Y, Saito Y, Kishimoto I, et al. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 2003; 107(19): 2406-8
27. Metcalfe BL, Huentelman MJ, Parilak LD, et al. Prevention of Cardiac Hypertrophy by Angiotensin II Type-2 Receptor Gene Transfer. Hypertension 2004; 43: 1233-8
28. Falcon BL, Stewart JM, Bourassa E, et al. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics 2004; 19: 255-61
29. Senbonmatsu T, Ichihara S, Price E Jr., Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 2000; 106: R25-9.
30. Ichihara S, Senbonmatsu T, Price E Jr., Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension. Circulation 2001; 104: 346-51.
31. Senbonmatsu T, Saito T, Landon EJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO 2003; 22: 6471-82.
32. Kurisu S, Ozono R, Oshima T, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41: 99-107.
33. Avila MD, Morgan JP, Yan X. Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure. J Biomed Biotechnol 2011; 141039. (doi: 10.1155/2011/141039)
34. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006; 47: 996-1002.
35. Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. Plos ONE 2009; 4: e5406.
36. Miyazaki M, Takai S. Tissue Angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 2006; 100: 391-7.
37. Albiston AL, Fernando RN, Yeatman HR, et al. Gene knockout of insulin-regulated aminopeptidase: Loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol Learn Mem 2010; 93: 19-30.
38. Numaguchi Y, Ishii M, Kubota R, et al. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 2102-8.
39. Lambert JD. NOX enzymes and the biology of reactive oxygen. Nature rev Immunol 2004; 4: 181-9.
40. Campuzano V, Segura-Puimedon M, Terrado V, et al. Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren syndrome. PLoS Genet 2012; 8: 2: e1002458
41. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010; 107: 15565-70.
42. Looi YH, Grieve DJ, Siva A, et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008; 51: 319-25.
43. Hingtgen SD. Nox-2 containing NADPH oxidase and Akt activation play a key role in Ang II-induced cardiomyocyte hypertrophy. Physiol Genom 2006; 180-91.
44. Fu Y, Zhang R, Lu D, et al. NOX2 is the primary source of angiotensin II-induced superoxide in the macula densa. Am J Physiol Regul Integr Comp Physiol 2010; 298(3): R707-12
45. Peterson JR, Burmeister MA, Tian X, et al. Genetic silencing of Nox2 and Nox4 reveals differential roles of these NADPH oxidase homologues in the vasopressor and dipsogenic effects of brain angiotensin II. Hypertension 2009; 54(5): 1106-14.
46. Carlstrom M, Lai EY, Ma Z, Patzak A, Brown RD, Persson AE. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am J Physiol Regul Integr Comp Physiol 2009; 296(1): R72-9.
47. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285(1): R117-24
48. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin IIinduced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271(38): 23317-21.
49. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74(6): 1141-8.
50. Touyz RM, Schiffrin EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 1999; 34(4): 976-82.
51. Karathanassis D, Stahelin RV, Bravo J, et al. Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction. EMBO J 2002; 21(19): 5057-68
52. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassegue B, Griendling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal 1999; 1(2): 167-79.
53. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-13
54. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 2005; 25(9): 1824-30
55. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006; 18: 69-82
56. Montezano AC, Burger D, Paravicini TM, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/ calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 2010; 106(8): 1363-73.
57. Lassegue B, Sorescu D, Szocs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88: 888-94
58. Gianni D, Bohl B, Courtneidge SA, Bokoch GM. The involvement of tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1. Mol Biol 2008; 19: 2984-94
59. Briones AM, Tabet F, Callera GE, et al. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertens 2011; 5(3): 137-53.
60. Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001; 31(11): 1456-64.
61. Ni W, Zhan Y, He H, Maynard E, Balschi JA, Oettgen P. Ets-1 is a critical transcriptional regulator of reactive oxygen species and p47(phox) gene expression in response to angiotensin II. Circ Res 2007; 101(10): 985-94.
62. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23(6): 981-87.
63. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 2008; 45: 1340-51.
64. Takac I, Schroder K, Zhang, et al. The E-loop is involved in Hydrogen peroxide formation by NADPH Oxidase Nox4. J Biol Chem 2011; 286: 13304-13
65. Guzik TJ, Chen W, Gongora MC, et al. Calcium-Dependent NOX5 NADPH oxidase Contributes to Vascular Oxidative Stress in Human Coronary Artery Disease. J Am Coll Cardiol 2008; 52: 1803-9.
66. Gavazzi G, Banfi B, Deffert C, et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006; 580: 497-504.
67. Mastuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005; 112: 2677-685.
68. Basset O, Deffert C, Foti M, et al. NADPH oxidase 1 deficiency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle. Antioxid Redox Signal 2009; 11: 2371-84.
69. Zimmerman, MC, Takapoo M, Jagadeesha DK, et al. Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells. Hypertension 2011; 58: 446-53.
70. phox(Nox2)-containing NADPH oxidase in angiogenesis in response to hindlimb ischemia. Circulation 2005; 111: 2347-55.
71. cip1and p53. Free Rad Biol Med 2007; 43: 976-86.
72. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40(4): 511-5
73. Craige, SM, Chen K, Pei Y, et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011; 124: 731-40.
74. Schroder K, Zhang M, Benkhoff, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012; 110: 1217-25.
75. Zhao Y, McLaughlin D, Robinson E, et al. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 2010; 70(22): 9287-97
76. Krijnen PA, Meischl C, Hack CE, et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 2003; 56(3): 194-9.
77. Zhang M, Brewer AC, Schroder K, et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA. 2010; 107(42): 18121-6
78. Brewer AC, Murray TV, Arno M, et al. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 2011; 51(1): 205-15.
79. Dai DF, Johnson SC, Villarin JJ, Chin MT, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Gaaq overexpression-induced heart failure. Circ Res 2011; 108(7): 837-46
80. Sibbing D, Pfeufer A, Perisic T, et al. Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. Eur Heart J 2011; 32(9): 1121-33
81. De Cavanagh EM, Toblli JE, Ferder L, et al. Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats. Cellular and molecular biology 2005; 51: 573-8
82. McNally JS, Saxena A, Cai H, Dikalov S, Harrison DG. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol 2005; 25(8): 1623-8.
83. Dikalov SI, Nazarewicz RR. Angiotensin II-induced production of mitochondrial ROS: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 2012. doi: 10.1089/ars.2012.4604
84. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 2010; 106(7): 1253-64
85. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102(4): 488-96.
86. 2emission from isolated Heart Mitochondria. J Biol Chem 2011; 286(38): 33669-77.
87. Kimura S, Zhang GX, Nishiyama A, et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005; 45: 438-44
88. Thuc LC, Teshima Y, Takahashi N, et al. Mitochondrial K(ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection. Apoptosis 2010; 15(6): 669-78.
89. Matejikova J, Kucharskai, Pinterova M, Pancza D, Ravingerova T. Protection Against Ischemia-Induced Ventricular Arrhythmias and Myocardial Dysfunction Conferred by Preconditioning in the Rat Heart: Involvement of Mitochondrial KATP Channels and Reactive Oxygen Species. Physiol Res 2009; 58: 9-19
90. Nishino Y, Miura T, Miki T, et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 upregulation in the late phase of cardioprotection. Cardiovas Res 2004; 61: 610-9.
91. Abadir PM, Foster DB, Crow M, et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci USA 2011; 108: 14849-54.
92. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005; 102: 9056-61
93. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4
94. Silberman GA, Fan TH, Liu H, et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 2010; 121: 519-28
95. Yamamoto E, Kataoka K, Shintaku H, et al. Novel Mechanism and Role of Angiotensin II Induced Vascular Endothelial Injury in Hypertensive Diastolic Heart Failure. Arterioscler Thromb Vasc Biol 2007; 27: 2569-75
96. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of Angiotensin II. Mol Endocrinol 2006; 20: 953-70.
97. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-71.
98. qoverexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997; 94: 8121-6.
99. 6receptor-Grr12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J 2008; 27: 3104-15.
100. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signaling pathways, Nat Rev Mol Cell Biol 2006; 7: 589-600.
101. Onohara N, Nishida M, Inoue R, et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 2006; 25: 5305-16.
102. Kiyonaka S, Kato K, Nishida M, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound, Proc Natl Acad Sci USA 2009; 106: 5400-5.
103. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009; 15: 75-83.
104. Thomas WG, Brandenburger Y, Autelitano DJ, et al. Adenoviraldirected expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002; 90(2): 135-42.
105. Shanmugam P, Valente AJ, Prabhu SD, et al. Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J Mol Cell Cardiol 2011; 50(6): 928-38
106. Yamada T, Akishita M, Pollman MJ, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Science 1998; 63(19): PL289-95.
107. 2-terminal kinase and p38 MAPK by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J Biol Chem 2005; 280: 18434-41.
108. 12/13-mediated production of reactive oxygen species is critical for angiotensin receptorinduced NFAT activation in cardiac fibroblasts. J Biol Chem 2005; 280: 23041-7.
109. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-606.
110. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23.
111. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008; 275: 3249-77.
112. 2, PtdIns(3)P, and PKC, in intracellular production of reactive oxygen species by the NADPH oxidase. Mol Cell 2003; 11: 35-47.
113. 2+influx contributes to Rac1-mediated production of reactive oxygen species in MLP-deficient mouse hearts. Biochem Biophys Res Commun 2011; 409: 108-13.
114. Nishida M, Hara Y, Yoshida T, Inoue R, Mori Y. TRP channels: Molecular diversity and physiological function. Microcirculation 2006; 13: 535-50.
115. 2+influx and protein scaffolding via TRPC3 sustain PKCsssand ERK activation in B cells. J Cell Sci 2010; 123: 927-38.
116. Price LS, Langeslag M, ten Klooster JP, Hordijk PL, Jalink K, Collard JG. Calcium signaling regulates translocation and activation of Rac. J Biol Chem 2003; 278: 39413-21.
117. Bienert GP, Moller AL, Kristiansen KA, et al. Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes. J Biol Chem 2007; 282: 1183-92.
118. Miller EW, Dickinson BC, Chang CJ. Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc Natl Acad Sci USA 2010; 107: 15681-6.
119. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-22.
120. Yoshida T, Inoue R, Morii T, et al. Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat Chem Biol 2006; 2: 596-607.
121. 2. Nat Chem Biol 2011; 7: 701-11.
122. Meng TC, Buckley DA, Galic S, Tiganis T, Tonks NK. Regulation of insulin signaling through reversible oxidation of the proteintyrosine phosphatases TC45 and PTP1B. J Biol Chem 2004; 279: 37716-25.
123. Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H. GHHi and Giio are target proteins of reactive oxygen species. Nature 2000; 408: 492-5.
124. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133: 462-74.
125. He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effect of aldosterone. Nat Med 2011; 17: 1610-8.
126. Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 2009; 206: 2889-96.
127. Domazet I, Holleran BJ, Martin, SS, et al. The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation. J Biol Chem 2009; 284: 11922-9.
128. Domazet I, Martin SS, Holleran BJ, et al. The fifth transmembrane domain of angiotensin II type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation. J Biol Chem 2009; 284: 31953-61.
129. Zhang J, Villacorta L, Chang L, et al. Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res 2010; 107: 540-8.
130. Nishida M, Suda R, Nagamatsu Y, et al. Pertussis toxin upregulates angiotensin type1 receptors through TLR4-mediated Rac activation. J Biol Chem 2010; 285: 15268-77.
131. 2+from endoplasmic reticulum to mitochondria plays a positive role in the early stage of UVor TNFTT-induced apoptosis. Biochem Biophys Res Commun 2008; 373: 42-7.
132. Tsuchiya Y, Asano T, Nakayama K, Kato Jr T, Karin M, Kamata H. Nuclear IKKHHHis an adaptor protein for IiiBBBBubiquitination and degradation in UV-induced NF-ddB activation. Mol Cell 2010; 39: 570-82.
133. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinasedependent activation of NADPH oxidase 2. Circ Res 2009; 104: 210-8.
134. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006; 47: 515-21.
135. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger TH. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
136. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007; 113: 210-26.
137. Shih H, Lee B, Lee RJ, Boyle AJ. The aging heart and postinfarction left ventricular remodeling. J. Am. Coll. Cardiol. 2011; 57: 9-17
138. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 2008; 7: 125-36.
139. Young A, Narita M. Connecting autophagy to senescence in pathophysiology. Curr Opin Cell Biol 2010; 22: 234-40.
140. McDuff FKE, Turner SD. Jailbreak: oncogene-induced senescence and its evasion. Cell Signal 2011; 23: 6-13.
141. Oudit GY, Kassiri Z, Patel MP, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75(1): 29-39
142. Li H, Liu Q, Wang N, Xu J. Correlation of different NADPH oxidase homologues with late endothelial progenitor cell senescence induced by angiotensin II: effect of telmisartan. Intern Med 2011; 50(16): 1631-42.
143. Herbert KE, Mistry Y, Hastings R, et al. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res 2008; 102(2): 201-8.
144. Modrick ML, Didion SP, Sigmund CD, et al. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 2009; 296(6): H1914-9.
145. Nguyen Dinh Cat A, Montezano AC, Burger D, et al. Angiotensin II, NADPH Oxidase, and Redox Signaling in the Vasculature. Antioxid Redox Signal 2012. doi: 10.1089/ars.2012.4641.
146. Lander HM, Milbank AJ, Tauras JM, et al. Redox regulation of cell signalling. Nature 1996; 381: 380-1
147. 2binds to and activates H-Ras. Proc Natl Acad Sci USA 2003; 100: 4772-7
148. INK4a. Cell 1997; 88: 593-602
149. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004; 432: 640-5
150. Kuster GM, Pimentel DR, Adachi T, et al. a-adrenergic receptorstimulated hypertrophy in adult rat ventricular myocytes is mediated via thiredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 2005; 111: 1192-8.
151. Pimentel DR, Adachi T, Ido Y, et al. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen speciesdependent Ras S-guanylation. J Mol Cell Cardiol 2006; 41: 613-22.
152. Raines KW, Cao G-L, Lee EK, Rosen GM, Shapiro P. Neuronal nitric oxide synthase-induced S-nitrosylation of H-Ras inhibits calcium ionophore-mediated extracellular-signal-regulated kinase activity. Biochem J 2006; 397: 329-36.
153. Sawa T, Zaki MH, Okamoto T, et al. Protein S-guanylation by the biological signal 8-nitroguanosine 3bb,5,-cyclic monophosphate. Nat Chem Biol 2007; 3: 727-35.
154. Nishida M, Sawa T, Kitajima N, et al. Hydrogen sulfide anion regulates redox signaling via electrophile sulfhydration. Nat Chem Biol 2012; 8: 714-24.